Natural Science Advisory Council
Jeffery W. Kelly


Fredonia Science Center
201 Houghton Hall
The State University of New York at Fredonia
Fredonia, NY 14063
Ph: 716-673-3285


Dr. Holly Lawson
Project Shepherd

Markus Kessler
Director of Facilities Planning

John Kijinski
Dean, College of Liberal Arts & Sciences

Betty Gossett
Associate Vice President for University Development

David Tiffany
Vice President for University Advancement & Executive Director of the Fredonia College Foundation

  jeffery Kelly

Jeffery W. Kelly


 

Graduation date from Fredonia: 1982
Major(s) while at Fredonia:

Chemistry

Other Education

Ph.D. Organic Chemistry (1986); University of North Carolina

NIH Postdoctoral Training (1987-1989); The Rockefeller University

Present professional positions

Chairman:


Lita Annenberg Hazen Professor of Chemistry


Chair of the Board:

Department of Molecular and Experimental Medicine, The Scripps Research Institute

Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute

The Skaggs Institute for Research

Office Phone/Fax:  (858) 784-9880
E-mail: jkelly@scripps.edu
Kelly Web Page

Past professional positions
Positions (academic)
2006 - 2008
Dean of Graduate and Postgraduate Studies, The Scripps Research Institute
2000 -- 2006

Dean and Vice President, Academic Affairs, The Scripps Research Institute

1997

Professor of Chemistry, Texas A&M University

Summer 1996 Visiting Investigator, Memorial Sloan-Kettering Institute
1989 - 1997 Assistant & Associate Professor of Chemistry, Texas A&M University
 
Professional affiliation(s), e.g. Boards, National Committees, etc.
 Co-founder

FoldRx Pharmaceuticals Boston, MA 2003 (with Susan Lindquist, MIT)  Enabled successful Tafamidis Phase I & II/III clinical trials at FoldRx. This compound was discovered by the Kelly Laboratory at Scripps to treat Familial Amyloid Polyneuropathy / Cardiomyopathy, and is likely to become the first EU & FDA approved drug that treats the underlying cause of a human amyloid disease.

     Co-founder

Proteostasis Therapeutics, Boston 2007 (with Andrew Dillin & Rick Morimoto). Developing Proteostasis Regulators, compounds that restore the cellular protein homeostasis network to youthful status to ameliorate numerous age-onset diseases.

Brief bio

Jeffery W. Kelly is the Lita Annenberg Hazen Professor of Chemistry and Chairman of Molecular and Experimental Medicine at The Scripps Research Institute. Until recently, he served as Dean of Graduate Studies and Vice President of Academic Affairs. Jeff received his B.S. in chemistry from SUNY Fredonia, his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill (1986) and performed post-doctoral research in Bioorganic chemistry at The Rockefeller University. His research focuses on the fundamental chemistry and biology of protein folding, as well as misfolding and aggregation diseases and the influence of small molecules on these processes in vivo. Kelly has co-founded two biotechnology companies, one of the small molecules discovered by his laboratory and developed by FoldRx pharmaceuticals is expected to become an FDA approved first-in-class drug in 2011 that halts the progression of familial amyloid polyneuropathy.


Page modified 7/15/14